Herbalife has announced a significant acquisition of Bioniq, a London-based company specializing in personalized supplements tailored to individual blood biomarkers and health data. The deal, valued at up to $150 million, is set to close in the second quarter of 2026, pending regulatory approvals. Herbalife will initially pay $55 million over five years, with additional performance-based payments contingent on Bioniq’s success.

This acquisition underscores a pivotal shift in the supplements market towards personalized nutrition, driven by data and individual health metrics. Bioniq’s innovative approach combines blood test data and lifestyle inputs to create customized nutrient formulations that adapt over time, aiming to optimize health and potentially extend healthspan. With a growing consumer base, including elite athletes, Bioniq has established a robust dataset that enhances its offerings.

For longevity professionals, this merger highlights the increasing importance of personalized health solutions in the supplement industry, suggesting a promising avenue for future therapeutic development and market growth.

Source: longevity.technology